Octapharma has received approval from the US FDA for a new 2-g formulation of Fibryga for use in patients with AFD.

Day One Biopharmaceuticals has concluded its acquisition of Mersana Therapeutics after meeting all the tender offer ...

According to Citi analysts, Amgen’s acquisition of Dark Blue could further drive the strength of Amgen’s early oncology ...

Ypsomed will establish its first manufacturing facility in the US. The company has selected Holly Springs in Wake County, ...

Cellenkos has received orphan drug designation from the US FDA for its investigational CK0804 Treg therapy to treat ...

Nimbus will apply its computational chemistry and structure-based drug design to a discovery programme in obesity treatment.

According to the registration form, Aktis intends to use a large portion of the IPO proceeds on the two programmes. Around ...

Zai Lab has received approval from China’s NMPA for the sNDA for Augtyro to treat adult patients with solid tumours ...

Reporter Ross Law and editors Abigail Beaney and Robert Barrie reflect on a busy 2025, along with discusing forecasts for ...

Takeda and Protagonist Therapeutics have jointly submitted a NDA seeking approval from the US FDA for rusfertide to treat ...

Arrowhead Pharmaceuticals has received authorisation from Health Canada for its siRNA medicine, Redemplo, for adults with FCS ...

The CDC now recommends 11 vaccines for routine administration in childhood, which it says better allows for “flexibility and ...